The DOI matches its Crossref record; 148 of the 148 references it cites were found in a registry or an index.
Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities
Open accessAbstract
Cancer immunotherapy has been firmly established as a new milestone for cancer therapy, with the development of multiple immune cells as therapeutic tools. Natural killer (NK) cells are innate immune cells endowed with potent cytolytic activity against tumors, and meanwhile act as regulatory cells for the immune system. The effecacy of NK cell-mediated immunotherapy can be enhanced by immune stimulants such as cytokines and antibodies, and adoptive transfer of activated NK cells expanded ex vivo. In addition, NK cells can arm themselves with chimeric antigen receptors (CARs), which may greatly enhance their anti-tumor activity. Most recently, extracellular vesicles (EVs) derived from NK cells show promising anti-tumor effects in preclinical studies. Herein, we carefully review the current progress in these NK cell-based immunotherapeutic strategies (NK cells combined with stimulants, adoptive transfer of NK cells, CAR-NK cells and NK EVs) for the treatment of cancers, and discussed the challenges and opportunities for opening a new horizon for cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Zhu, L., Oh, J. M., Gangadaran, P., Kalimuthu, S., Baek, S. H., Jeong, S. Y., Lee, S., Lee, J., & Ahn, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00824 · Cited by 88
RetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Biological properties of extracellular vesicles and their physiological functions
Yáñez‐Mó, M., Siljander, P. R. ‐., Andreu, Z., Bedina Zavec, A., Borràs, F. E., Buzas, E. I., Buzas, K., Casal, E., Cappello, F., Carvalho, J., et al. (2015) · Journal of Extracellular Vesicles · doi:10.3402/jev.v4.27066 · Cited by 5,926
Exosomes: composition, biogenesis and function
Théry, C., Zitvogel, L., & Amigorena, S. (2002) · Nature Reviews Immunology · doi:10.1038/nri855 · Cited by 5,346
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes
Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., & Wood, M. J. A. (2011) · Nature Biotechnology · doi:10.1038/nbt.1807 · Cited by 4,930
Functions of natural killer cells
Vivier, E., Tomasello, E., Baratin, M., Walzer, T., & Ugolini, S. (2008) · Nature Immunology · doi:10.1038/ni1582 · Cited by 3,943
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., et al. (2002) · Science · doi:10.1126/science.1068440 · Cited by 3,380
Innate or adaptive immunity? The example of natural killer cells
Vivier, E., Raulet, D. H., Moretta, A., Caligiuri, M. A., Zitvogel, L., Lanier, L. L., Yokoyama, W. M., & Ugolini, S. (2011) · Science · doi:10.1126/science.1198687 · Cited by 2,824
Miller, J. S., Soignier, Y., Panoskaltsis-Mortari, A., McNearney, S. A., Yun, G. H., Fautsch, S. K., McKenna, D., Le, C., Defor, T. E., Burns, L. J., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2974 · Cited by 1,903
Helmlinger, G., Yuan, F., Dellian, M., & Jain, R. K. (1997) · Nature Medicine · doi:10.1038/nm0297-177 · Cited by 1,628
Microenvironmental pH Is a Key Factor for Exosome Traffic in Tumor Cells
Parolini, I., Federici, C., Raggi, C., Lugini, L., Palleschi, S., De Milito, A., Coscia, C., Iessi, E., Logozzi, M., Molinari, A., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.041152 · Cited by 1,555
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512
Bruhns, P., Iannascoli, B., England, P., Mancardi, D. A., Fernandez, N., Jorieux, S., & Daëron, M. (2009) · Blood · doi:10.1182/blood-2008-09-179754 · Cited by 1,479
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Sanmamed, M. F., & Chen, L. (2018) · Cell · doi:10.1016/j.cell.2018.09.035 · Cited by 1,392
The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design
Waldmann, T. A. (2006) · Nature Reviews Immunology · doi:10.1038/nri1901 · Cited by 1,178
NK cells and cancer: you can teach innate cells new tricks
Morvan, M. G., & Lanier, L. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.5 · Cited by 1,162
Natural Killer Cells: Development, Maturation, and Clinical Utilization
Abel, A. M., Yang, C., Thakar, M. S., & Malarkannan, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01869 · Cited by 1,150
Zhang, Q., Bi, J., Zheng, X., Chen, Y., Wang, H., Wu, W., Wang, Z., Wu, Q., Peng, H., Wei, H., et al. (2018) · Nature Immunology · doi:10.1038/s41590-018-0132-0 · Cited by 1,122
Targeting natural killer cells in cancer immunotherapy
Guillerey, C., Huntington, N. D., & Smyth, M. J. (2016) · Nature Immunology · doi:10.1038/ni.3518 · Cited by 1,066
Palumbo, J. S., Talmage, K. E., Massari, J. V., La Jeunesse, C. M., Flick, M. J., Kombrinck, K. W., Jirousková, M., & Degen, J. L. (2005) · Blood · doi:10.1182/blood-2004-06-2272 · Cited by 999
Li, Y., Hermanson, D. L., Moriarity, B. S., & Kaufman, D. S. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.06.002 · Cited by 981
Yang, T., Martin, P., Fogarty, B., Brown, A., Schurman, K., Phipps, R., Yin, V. P., Lockman, P., & Bai, S. (2015) · Pharmaceutical Research · doi:10.1007/s11095-014-1593-y · Cited by 975
Regulation of human NK-cell cytokine and chemokine production by target cell recognition
Fauriat, C., Long, E. O., Ljunggren, H.-G., & Bryceson, Y. T. (2010) · Blood · doi:10.1182/blood-2009-08-238469 · Cited by 891
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
Ohaegbulam, K. C., Assal, A., Lazar-Molnar, E., Yao, Y., & Zang, X. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.10.009 · Cited by 843
Lysis of tumor cells by natural killer cells in mice is impeded by platelets.
Nieswandt, B., Hafner, M., Echtenacher, B., & Männel, D. N. (1999) · PubMed · Cited by 832
Induction of Lymphocyte Apoptosis by Tumor Cell Secretion of FasL-bearing Microvesicles
Andreola, G., Rivoltini, L., Castelli, C., Huber, V., Perego, P., Deho, P., Squarcina, P., Accornero, P., Lozupone, F., Lugini, L., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011624 · Cited by 774
Exosome Function: From Tumor Immunology to Pathogen Biology
Schorey, J. S., & Bhatnagar, S. (2008) · Traffic · doi:10.1111/j.1600-0854.2008.00734.x · Cited by 758
Conlon, K. C., Lugli, E., Welles, H. C., Rosenberg, S. A., Fojo, A. T., Morris, J. C., Fleisher, T. A., Dubois, S. P., Perera, L. P., Stewart, D. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.3329 · Cited by 711
Remote control of therapeutic T cells through a small molecule–gated chimeric receptor
Wu, C.-Y., Roybal, K. T., Puchner, E. M., Onuffer, J., & Lim, W. A. (2015) · Science · doi:10.1126/science.aab4077 · Cited by 687
Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
Hegde, M., Mukherjee, M., Grada, Z., Pignata, A., Landi, D., Navai, S. A., Wakefield, A., Fousek, K., Bielamowicz, K., Chow, K. K. H., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83416 · Cited by 677
Imai, C., Iwamoto, S., & Campana, D. (2005) · Blood · doi:10.1182/blood-2004-12-4797 · Cited by 659
NK cell-based immunotherapy for malignant diseases
Cheng, M., Chen, Y., Xiao, W., Sun, R., & Tian, Z. (2013) · Cellular & Molecular Immunology · doi:10.1038/cmi.2013.10 · Cited by 631
Zah, E., Lin, M.-Y., Silva-Benedict, A., Jensen, M. C., & Chen, Y. Y. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0231 · Cited by 607
Re-Engineering Extracellular Vesicles as Smart Nanoscale Therapeutics
Armstrong, J. P. K., Holme, M. N., & Stevens, M. M. (2017) · ACS Nano · doi:10.1021/acsnano.6b07607 · Cited by 602
Perforin-mediated target-cell death and immune homeostasis
Voskoboinik, I., Smyth, M. J., & Trapani, J. A. (2006) · Nature reviews. Immunology · doi:10.1038/nri1983 · Cited by 592
Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’
Levin, A. M., Bates, D. L., Ring, A. M., Krieg, C., Lin, J. T., Su, L., Moraga, I., Raeber, M. E., Bowman, G. R., Novick, P., et al. (2012) · Nature · doi:10.1038/nature10975 · Cited by 552
Huber, V., Fais, S., Iero, M., Lugini, L., Canese, P., Squarcina, P., Zaccheddu, A., Colone, M., Arancia, G., Gentile, M., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.045 · Cited by 524
Therapeutic Applications of Extracellular Vesicles: Clinical Promise and Open Questions
György, B., Hung, M. E., Breakefield, X. O., & Leonard, J. N. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124630 · Cited by 515
Balancing natural killer cell activation through paired receptors
Martinet, L., & Smyth, M. J. (2015) · Nature Reviews Immunology · doi:10.1038/nri3799 · Cited by 485
Parkhurst, M. R., Riley, J. P., Dudley, M. E., & Rosenberg, S. A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1347 · Cited by 475
Exosomes Derived From Natural Killer Cells Exert Therapeutic Effect in Melanoma
Zhu, L., Kalimuthu, S., Gangadaran, P., Oh, J. M., Lee, H. W., Baek, S. H., Jeong, S. Y., Lee, S.-W., Lee, J., & Ahn, B.-C. (2017) · Theranostics · doi:10.7150/thno.18752 · Cited by 471
Kopp, H.-G., Placke, T., & Salih, H. R. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2123 · Cited by 469
Treatment of patients with advanced cancer with the natural killer cell line NK-92
Tonn, T., Schwabe, D., Klingemann, H. G., Becker, S., Esser, R., Koehl, U., Suttorp, M., Seifried, E., Ottmann, O. G., & Bug, G. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.06.017 · Cited by 467
Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell–driven tumor immunity
Ferrari de Andrade, L., Tay, R. E., Pan, D., Luoma, A. M., Ito, Y., Badrinath, S., Tsoucas, D., Franz, B., May, K. F., Harvey, C. J., et al. (2018) · Science · doi:10.1126/science.aao0505 · Cited by 459
Immune Surveillance Properties of Human NK Cell-Derived Exosomes
Lugini, L., Cecchetti, S., Huber, V., Luciani, F., Macchia, G., Spadaro, F., Paris, L., Abalsamo, L., Colone, M., Molinari, A., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101988 · Cited by 453
Lazetic, S., Chang, C., Houchins, J. P., Lanier, L. L., & Phillips, J. H. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.11.4741 · Cited by 447
Geller, M. A., Cooley, S., Judson, P. L., Ghebre, R., Carson, L. F., Argenta, P. A., Jonson, A. L., Panoskaltsis-Mortari, A., Curtsinger, J., McKenna, D., et al. (2011) · Cytotherapy · doi:10.3109/14653249.2010.515582 · Cited by 436
Melero, I., Rouzaut, A., Motz, G. T., & Coukos, G. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0985 · Cited by 435
Arai, S., Meagher, R., Swearingen, M., Myint, H., Rich, E., Martinson, J., & Klingemann, H. (2008) · Cytotherapy · doi:10.1080/14653240802301872 · Cited by 434
Natural killer cell biology: An update and future directions
Campbell, K. S., & Hasegawa, J. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.07.006 · Cited by 416
Knorr, D. A., Ni, Z., Hermanson, D., Hexum, M. K., Bendzick, L., Cooper, L. J. N., Lee, D. A., & Kaufman, D. S. (2013) · Stem Cells Translational Medicine · doi:10.5966/sctm.2012-0084 · Cited by 415
Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells
Klingemann, H., Boissel, L., & Toneguzzo, F. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00091 · Cited by 414
Effect of tumor cells and tumor microenvironment on NK‐cell function
Vitale, M., Cantoni, C., Pietra, G., Mingari, M. C., & Moretta, L. (2014) · European Journal of Immunology · doi:10.1002/eji.201344272 · Cited by 412
Wrangle, J. M., Velcheti, V., Patel, M. R., Garrett-Mayer, E., Hill, E. G., Ravenel, J. G., Miller, J. S., Farhad, M., Anderton, K., Lindsey, K., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30148-7 · Cited by 412
Romee, R., Cooley, S., Berrien-Elliott, M. M., Westervelt, P., Verneris, M. R., Wagner, J. E., Weisdorf, D. J., Blazar, B. R., Ustun, C., DeFor, T. E., et al. (2018) · Blood · doi:10.1182/blood-2017-12-823757 · Cited by 409
Romagné, F., André, P., Spee, P., Zahn, S., Anfossi, N., Gauthier, L., Capanni, M., Ruggeri, L., Benson, D. M., Blaser, B. W., et al. (2009) · Blood · doi:10.1182/blood-2009-02-206532 · Cited by 408
Chiesa, M. D., Carlomagno, S., Frumento, G., Balsamo, M., Cantoni, C., Conte, R., Moretta, L., Moretta, A., & Vitale, M. (2006) · Blood · doi:10.1182/blood-2006-03-006700 · Cited by 399
Vallera, D. A., Felices, M., McElmurry, R., McCullar, V., Zhou, X., Schmohl, J. U., Zhang, B., Lenvik, A. J., Panoskaltsis-Mortari, A., Verneris, M. R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2710 · Cited by 391
Heterogeneity of Natural Killer Cells
Ortaldo, J. (1984) · Annual Review of Immunology · doi:10.1146/annurev.immunol.2.1.359 · Cited by 358
O’Sullivan, T. E., Sun, J. C., & Lanier, L. L. (2015) · Immunity · doi:10.1016/j.immuni.2015.09.013 · Cited by 349
Rothe, A., Sasse, S., Topp, M. S., Eichenauer, D. A., Hummel, H., Reiners, K. S., Dietlein, M., Kuhnert, G., Kessler, J., Buerkle, C., et al. (2015) · Blood · doi:10.1182/blood-2014-12-614636 · Cited by 337
Campbell, K. S., & Purdy, A. K. (2011) · Immunology · doi:10.1111/j.1365-2567.2010.03398.x · Cited by 329
NK-92: an ‘off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy
Suck, G., Odendahl, M., Nowakowska, P., Seidl, C., Wels, W. S., Klingemann, H. G., & Tonn, T. (2016) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-015-1761-x · Cited by 328
Raimondo, F., Morosi, L., Chinello, C., Magni, F., & Pitto, M. (2011) · PROTEOMICS · doi:10.1002/pmic.201000422 · Cited by 326
Zhang, C., Oberoi, P., Oelsner, S., Waldmann, A., Lindner, A., Tonn, T., & Wels, W. S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00533 · Cited by 306
NK cell-based immunotherapy for cancer
Fang, F., Xiao, W., & Tian, Z. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.07.009 · Cited by 306
Cekic, C., Day, Y.-J., Sag, D., & Linden, J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3583 · Cited by 304
A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission
Vey, N., Bourhis, J.-H., Boissel, N., Bordessoule, D., Prebet, T., Charbonnier, A., Etienne, A., Andre, P., Romagne, F., Benson, D., et al. (2012) · Blood · doi:10.1182/blood-2012-06-437558 · Cited by 278
Mao, Y., Sarhan, D., Steven, A., Seliger, B., Kiessling, R., & Lundqvist, A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0635 · Cited by 274
Are natural killer cells superior CAR drivers?
Klingemann, H. (2014) · OncoImmunology · doi:10.4161/onci.28147 · Cited by 270
Woll, P. S., Grzywacz, B., Tian, X., Marcus, R. K., Knorr, D. A., Verneris, M. R., & Kaufman, D. S. (2009) · Blood · doi:10.1182/blood-2008-06-165225 · Cited by 268
Uherek, C., Tonn, T., Uherek, B., Becker, S., Schnierle, B., Klingemann, H.-G., & Wels, W. (2002) · Blood · doi:10.1182/blood.v100.4.1265.h81602001265_1265_1273 · Cited by 262
Burns, L. J., Weisdorf, D. J., DeFor, T. E., Vesole, D. H., Repka, T. L., Blazar, B. R., Burger, S. R., Panoskaltsis-Mortari, A., Keever-Taylor, C. A., Zhang, M.-J., et al. (2003) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704086 · Cited by 252
Krause, S. W., Gastpar, R., Andreesen, R., Gross, C., Ullrich, H., Thonigs, G., Pfister, K., & Multhoff, G. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0683 · Cited by 246
Benson, D. M., Hofmeister, C. C., Padmanabhan, S., Suvannasankha, A., Jagannath, S., Abonour, R., Bakan, C., Andre, P., Efebera, Y., Tiollier, J., et al. (2012) · Blood · doi:10.1182/blood-2012-06-438028 · Cited by 244
Induced Pluripotent Stem Cell-Derived Natural Killer Cells for Treatment of Ovarian Cancer
Hermanson, D. L., Bendzick, L., Pribyl, L., McCullar, V., Vogel, R. I., Miller, J. S., Geller, M. A., & Kaufman, D. S. (2016) · Stem Cells · doi:10.1002/stem.2230 · Cited by 242
Varchetta, S., Gibelli, N., Oliviero, B., Nardini, E., Gennari, R., Gatti, G., Silva, L. S., Villani, L., Tagliabue, E., Ménard, S., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2068 · Cited by 240
Jong, A. Y., Wu, C., Li, J., Sun, J., Fabbri, M., Wayne, A. S., & Seeger, R. C. (2017) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2017.1294368 · Cited by 239
Shah, N. N., Baird, K., Delbrook, C. P., Fleisher, T. A., Kohler, M. E., Rampertaap, S., Lemberg, K., Hurley, C. K., Kleiner, D. E., Merchant, M. S., et al. (2015) · Blood · doi:10.1182/blood-2014-07-592881 · Cited by 238
Gleason, M. K., Verneris, M. R., Todhunter, D. A., Zhang, B., McCullar, V., Zhou, S. X., Panoskaltsis-Mortari, A., Weiner, L. M., Vallera, D. A., & Miller, J. S. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0692 · Cited by 238
Human Embryonic Stem Cell-Derived NK Cells Acquire Functional Receptors and Cytolytic Activity
Woll, P. S., Martin, C. H., Miller, J. S., & Kaufman, D. S. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.8.5095 · Cited by 233
Floros, T., & Tarhini, A. A. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.015 · Cited by 229
Wiernik, A., Foley, B., Zhang, B., Verneris, M. R., Warlick, E., Gleason, M. K., Ross, J. A., Luo, X., Weisdorf, D. J., Walcheck, B., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0505 · Cited by 226
Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering
Daher, M., & Rezvani, K. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.03.013 · Cited by 224
Han, K.-P., Zhu, X., Liu, B., Jeng, E., Kong, L., Yovandich, J. L., Vyas, V. V., Marcus, W. D., Chavaillaz, P.-A., Romero, C. A., et al. (2011) · Cytokine · doi:10.1016/j.cyto.2011.09.028 · Cited by 223
Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy
Srivastava, S., & Riddell, S. R. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701155 · Cited by 220
Dolstra, H., Roeven, M. W. H., Spanholtz, J., Hangalapura, B. N., Tordoir, M., Maas, F., Leenders, M., Bohme, F., Kok, N., Trilsbeek, C., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2981 · Cited by 210
Benson, D. M., Bakan, C. E., Zhang, S., Collins, S. M., Liang, J., Srivastava, S., Hofmeister, C. C., Efebera, Y., Andre, P., Romagne, F., et al. (2011) · Blood · doi:10.1182/blood-2011-06-360255 · Cited by 208
Altvater, B., Landmeier, S., Pscherer, S., Temme, J., Schweer, K., Kailayangiri, S., Campana, D., Juergens, H., Pule, M., & Rossig, C. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2810 · Cited by 206
Iida, S., Misaka, H., Inoue, M., Shibata, M., Nakano, R., Yamane-Ohnuki, N., Wakitani, M., Yano, K., Shitara, K., & Satoh, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2619 · Cited by 206
The Common Cytokine Receptor γ Chain Family of Cytokines
Lin, J.-X., & Leonard, W. J. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028449 · Cited by 200
Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas
Kruschinski, A., Moosmann, A., Poschke, I., Norell, H., Chmielewski, M., Seliger, B., Kiessling, R., Blankenstein, T., Abken, H., & Charo, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804788105 · Cited by 197
Miller, J. S., Morishima, C., McNeel, D. G., Patel, M. R., Kohrt, H. E. K., Thompson, J. A., Sondel, P. M., Wakelee, H. A., Disis, M. L., Kaiser, J. C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2451 · Cited by 197
McGilvray, R. W., Eagle, R. A., Watson, N. F. S., Al-Attar, A., Ball, G., Jafferji, I., Trowsdale, J., & Durrant, L. G. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0991 · Cited by 196 · cited 1×
“For example, high levels of NKG2D (Natural-killer Group 2, Member D) ligands are detected in the early stages of colorectal cancer, but their expression decreases as the disease progresses (8).”
BackgroundOelsner, S., Friede, M. E., Zhang, C., Wagner, J., Badura, S., Bader, P., Ullrich, E., Ottmann, O. G., Klingemann, H., Tonn, T., et al. (2017) · Cytotherapy · doi:10.1016/j.jcyt.2016.10.009 · Cited by 188
Genßler, S., Burger, M. C., Zhang, C., Oelsner, S., Mildenberger, I., Wagner, M., Steinbach, J. P., & Wels, W. S. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1119354 · Cited by 187
Davila, M. L., Kloss, C. C., Gunset, G., & Sadelain, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061338 · Cited by 185
Jochems, C., Hodge, J. W., Fantini, M., Fujii, R., Morillon, Y. M., Greiner, J. W., Padget, M. R., Tritsch, S. R., Yok Tsang, K., Campbell, K. S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13411 · Cited by 182
Boyiadzis, M., Agha, M., Redner, R. L., Sehgal, A., Im, A., Hou, J.-Z., Farah, R., Dorritie, K. A., Raptis, A., Lim, S. H., et al. (2017) · Cytotherapy · doi:10.1016/j.jcyt.2017.07.008 · Cited by 178
Biological roles and potential applications of immune cell‐derived extracellular vesicles
Wen, C., Seeger, R. C., Fabbri, M., Wang, L., Wayne, A. S., & Jong, A. Y. (2017) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2017.1400370 · Cited by 176
Impact of FASL-induced apoptosis in the elimination of tumor cells by NK cells
Screpanti, V., Wallin, R. P. A., Grandien, A., & Ljunggren, H.-G. (2005) · Molecular Immunology · doi:10.1016/j.molimm.2004.07.033 · Cited by 172
Utilizing Chimeric Antigen Receptors to Direct Natural Killer Cell Activity
Hermanson, D. L., & Kaufman, D. S. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00195 · Cited by 172
Carlsten, M., Korde, N., Kotecha, R., Reger, R., Bor, S., Kazandjian, D., Landgren, O., & Childs, R. W. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1108 · Cited by 166
Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers
Mushtaq, M. U., Papadas, A., Pagenkopf, A., Flietner, E., Morrow, Z., Chaudhary, S. G., & Asimakopoulos, F. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0376-0 · Cited by 165
Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells
Ruggeri, L., Urbani, E., Andre, P., Mancusi, A., Tosti, A., Topini, F., Blery, M., Animobono, L., Romagne, F., Wagtmann, N., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.135301 · Cited by 160
Human natural killer cell development in secondary lymphoid tissues
Freud, A. G., Yu, J., & Caligiuri, M. A. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.02.008 · Cited by 150
Davis, Z., Vallera, D. A., Miller, J. S., & Felices, M. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.07.011 · Cited by 150
Vey, N., Karlin, L., Sadot‐Lebouvier, S., Broussais, F., Berton-Rigaud, D., Rey, J., Charbonnier, A., Marie, D., André, P., Paturel, C., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24832 · Cited by 149
Exosomes and the blood–brain Barrier: Implications for Neurological Diseases
Wood, M. J. A., O’Loughlin, A. J., & Lakhal, S. (2011) · Therapeutic Delivery · doi:10.4155/tde.11.83 · Cited by 148
Pahl, J. H. W., Koch, J., Götz, J.-J., Arnold, A., Reusch, U., Gantke, T., Rajkovic, E., Treder, M., & Cerwenka, A. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0550 · Cited by 145
Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds
Lagrue, K., Carisey, A. F., Morgan, D. J., Chopra, R., & Davis, D. M. (2015) · Blood · doi:10.1182/blood-2015-01-625004 · Cited by 139
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma
Korde, N., Carlsten, M., Lee, M.-J., Minter, A., Tan, E. M., Kwok, M., Manasanch, E. E., Bhutani, M., Tageja, N., Roschewski, M. J., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.103085 · Cited by 137
Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution
Tzeng, A., Kwan, B. H., Opel, C. F., Navaratna, T. A., & Wittrup, K. D. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1416159112 · Cited by 125
Natural killer cell immunotherapies against cancer: checkpoint inhibitors and more
Chiossone, L., Vienne, M., Kerdiles, Y. M., & Vivier, É. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.08.003 · Cited by 121
Chan, W. K., Kang, S., Youssef, Y., Glankler, E. N., Barrett, E. R., Carter, A. M., Ahmed, E. H., Prasad, A., Chen, L., Zhang, J., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0649 · Cited by 120
Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells
Kim, N., & Kim, H. S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02041 · Cited by 120
Ex vivo expansion of natural killer cells for clinical applications
Klingemann, H.-G., & Martinson, J. (2004) · Cytotherapy · doi:10.1080/14653240310004548 · Cited by 117
Ito, S., Bollard, C. M., Carlsten, M., Melenhorst, J. J., Biancotto, A., Wang, E., Chen, J., Kotliarov, Y., Cheung, F., Xie, Z., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.50 · Cited by 117
Wu, J., Fu, J., Zhang, M., & Liu, D. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0188-3 · Cited by 117
Natural Killer Cell Adoptive Transfer Therapy: Exploiting the First Line of Defense Against Cancer
Davis, Z., Felices, M., Verneris, M. R., & Miller, J. S. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000156 · Cited by 114
IGF-1 promotes the development and cytotoxic activity of human NK cells
Ni, F., Sun, R., Fu, B., Wang, F., Guo, C., Tian, Z., & Wei, H. (2013) · Nature Communications · doi:10.1038/ncomms2484 · Cited by 113
Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches
Carotta, S. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00152 · Cited by 107
Schmohl, J. U., Felices, M., Taras, E. P., Miller, J. S., & Vallera, D. A. (2016) · Molecular Therapy · doi:10.1038/mt.2016.88 · Cited by 100
Eguizábal, C., Zenarruzabeitia, O., Monge, J., Santos, S. D. M., Vesga, M. Á., Maruri, N., Arrieta, A., n, M. R., Tamayo-Orbegozo, E., Amo, L., et al. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00439 · Cited by 99
Infusions of Allogeneic Natural Killer Cells as Cancer Therapy
Leung, W. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1766 · Cited by 98
Fais, S. (2012) · OncoImmunology · doi:10.4161/onci.22337 · Cited by 84
Srivastava, S., Pelloso, D., Feng, H., Voiles, L., Lewis, D., Hašková, Z., Whitacre, M., Trulli, S. H., Chen, Y.-J., Toso, J. F., et al. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1403-0 · Cited by 80
Wong, H. C., Jeng, E. K., & Rhode, P. R. (2013) · OncoImmunology · doi:10.4161/onci.26442 · Cited by 80
Xu, Y., Sun, J., Sheard, M. A., Tran, H. C., Wan, Z., Liu, W. Y., Asgharzadeh, S., Sposto, R., Wu, H. W., & Seeger, R. C. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1466-y · Cited by 75
Self-citationNechansky, A., Schuster, M., Jost, W. H., Siegl, P., Wiederkum, S., Gorr, G., & Kircheis, R. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2006.08.013 · Cited by 70
Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy
Ghasemi, R., Lazear, E., Wang, X., Arefanian, S., Zheleznyak, A., Carreno, B. M., Higashikubo, R., Gelman, A. E., Kreisel, D., Fremont, D. H., et al. (2016) · Nature Communications · doi:10.1038/ncomms12878 · Cited by 69
Bruenke, J., Barbin, K., Kunert, S., Lang, P., Pfeiffer, M. M., Stieglmaier, K., NIETHAMMER, D., Stockmeyer, B., Peipp, M., Repp, R., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05414.x · Cited by 63
Oberschmidt, O., Kloeß, S., & Koehl, U. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00654 · Cited by 63
Acidic pH Inhibits Non-MHC-Restricted Killer Cell Functions
Fischer, B., Müller, B., Fischer, K.-G., Baur, N., & Kreutz, W. (2000) · Clinical Immunology · doi:10.1006/clim.2000.4904 · Cited by 62
TriKEs and BiKEs join CARs on the cancer immunotherapy highway
Tay, S. S., Carol, H., & Biro, M. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1198455 · Cited by 57
Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs: a Perspective
Cifaldi, L., Locatelli, F., Marasco, E., Moretta, L., & Pistoia, V. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.10.002 · Cited by 57
An Fc-optimized CD133 antibody for induction of NK cell reactivity against myeloid leukemia
Koerner, S., Andre, M. C., Leibold, J., Kousis, P. C., Kübler, A., Pal, M., Haen, S. P., Bühring, H.-J., Grosse-Hovest, L., Jung, G., et al. (2016) · Leukemia · doi:10.1038/leu.2016.194 · Cited by 56
Efficient gene transfer into primary human natural killer cells by retroviral transduction.
Guvén, H., Konstantinidis, K., Alici, E., Aints, A., Abedi-Valugerdi, M., Christensson, B., Ljunggren, H., & Dilber, M. (2005) · Experimental Hematology · doi:10.1016/j.exphem.2005.07.006 · Cited by 55
Natural killer cell immunotherapy to target stem-like tumor cells
Grossenbacher, S. K., Canter, R. J., & Murphy, W. J. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0124-2 · Cited by 53
IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation
Sim, G. C., Liu, C., Wang, E., Liu, H., Creasy, C. A., Dai, Z., Overwijk, W. W., Roszik, J., Marincola, F. M., Hwu, P., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0195 · Cited by 52
“NextGen” Biologics: Bispecific Antibodies and Emerging Clinical Results
Thakur, A. B., & Lum, L. G. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1150996 · Cited by 48
Kellner, C., Bruenke, J., Horner, H., Schubert, J. E. A., Schwenkert, M., Mentz, K., Barbin, K., Stein, C., Peipp, M., & Stockmeyer, B. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.01.020 · Cited by 47
Albertini, M. R., Yang, R. K., Ranheim, E. A., Hank, J. A., Zuleger, C., Weber, S. M., Neuman, H. B., Hartig, G., Weigel, T. L., Mahvi, D., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2223-z · Cited by 45
Lowe, E. L., Truscott, L. C., & Oliveira, S. N. D. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3684-7_20 · Cited by 37
Kim, Y. M., Park, J. S., Kim, S. K., Jung, K. M., Hwang, Y. S., Han, M., Lee, H. J., Seo, H. W., Suh, J., Han, B. K., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.03.021 · Cited by 30
Natural killer cells for cancer immunotherapy: a new CAR is catching up
(2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.01.018 · Cited by 25
Cited by
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0297-y · Cited by 1,472
Immune Cell Membrane‐Coated Biomimetic Nanoparticles for Targeted Cancer Therapy
Oroojalian, F., Beygi, M., Baradaran, B., Mokhtarzadeh, A., & Shahbazi, M. (2021) · Small · doi:10.1002/smll.202006484 · Cited by 528
Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors
Melaiu, O., Lucarini, V., Cifaldi, L., & Fruci, D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03038 · Cited by 419
Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets
Yang, J., Xu, J., Wang, W., Zhang, B., Yu, X., & Shi, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01480-x · Cited by 388
Ultrasound-Responsive Cavitation Nuclei for Therapy and Drug Delivery
Kooiman, K., Roovers, S., Langeveld, S. A. G., Kleven, R. T., Dewitte, H., O'Reilly, M. A., Escoffre, J.-M., Bouakaz, A., Verweij, M. D., Hynynen, K., et al. (2020) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2020.01.002 · Cited by 359
Metadata
- Authors
- Hu, W., Wang, G., Huang, D., Sui, M., & Xu, Y.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2019-05-31
- Volume
- 10
- Pages
- 1205-1205
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2946995077
- Cited by
- 398
- References
- 148
- FWCI
- 19.87
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.